Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential for new option to improve convenience for patients -

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the presentation of positive data for VELCADE, the market-leading therapy for patients with multiple myeloma (MM) who have received at least one prior therapy. These data include results from a Phase II trial for subcutaneous (SC) administration of VELCADE, a new option under evaluation. Results were also presented from the international Phase III trial of VELCADE + DOXIL, which served as the basis for the recent U.S. approval of the combination and showed significant improvement in time to disease progression compared to VELCADE alone, the current standard of care. The VELCADE + DOXIL abstract was selected by the Best of the American Society of Clinical Oncology (ASCO) Program Committee as one of the premier abstracts at the 43rd Annual Meeting in Chicago.

"We and our partner Johnson & Johnson Pharmaceutical Research and Development L.L.C. continue to develop new clinical data that reinforce the role of VELCADE as the U.S. market-leading therapy in previously treated multiple myeloma," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "These data demonstrate that VELCADE in combination with another active agent can further strengthen the unparalleled impact of VELCADE. We are aggressively pursuing development of a subcutaneous delivery form to broaden alternatives for patients who prefer to receive VELCADE treatment at home."

Prospective Comparison of Subcutaneous to Intravenous Administration of Bortezomib in Patients with Multiple Myeloma: Pharmacokinetics, Efficacy and Toxicity (Abstract #8046)

This randomized trial evaluated the pharmacokinetics/pharmacodynamics (PK/PD), toxicity and response rate of VELCADE in patients treated with either an SC or intravenous
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies

Post Your Comments:
(Date:11/20/2009)...irstCall/ -- Medco Health Solutions, Inc (NYSE: ... American healthcare through an advanced, wired ph...quality clinical care and fundamentally bending th...or the benefit of patients and payors alike. ,,...ts strategy enable "Smarter Medicine" to help addr...
(Date:11/20/2009)...re/ -- Reportlinker.com announces that a new marke..., Pipettes & Pipettors - A Global Market P...164373/Pipettes--Pipettors---A-Global-Market-Persp...r&utm_campaign=prnewswire ,, Pipettes and...research laboratory. Large-scale applications in l...
(Date:11/20/2009)...re/ -- Reportlinker.com announces that a new marke..., Medical Adhesives and Sealants - A US Market...242/Medical-Adhesives-and-Sealants---A-US-Market-R...&utm_campaign=prnewswire ,, The use of me...e in medical devices and equipments. Cutting edge ...
Breaking Medicine Technology:Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 2Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 3Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 4Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6Insurance and HMO Industries Spend Nearly 24700 000 Per Day to Kill Health Care Reform Measures 57243 1Insurance and HMO Industries Spend Nearly 24700 000 Per Day to Kill Health Care Reform Measures 57243 2Sigma Aldrich to Present at the UBS Global Life Sciences Conference on Monday September 21 2009 14064 1Pelosi Remarks at Democratic Steering and Policy Committee Forum on Health Insurance Reform 57234 1Pelosi Remarks at Democratic Steering and Policy Committee Forum on Health Insurance Reform 57234 2Pelosi Remarks at Democratic Steering and Policy Committee Forum on Health Insurance Reform 57234 3
...07 - Clinical results from a,Phase II study presen...ciety (AHS) annual meeting showed that MK-0974, an...ide (CGRP),receptor antagonist, significantly impr...ompared to placebo, and the relief was,sustained t...ted in,the study. Responses specific to other meas...
... weeks achieved an SVR rate at,least comparable to...e favorable quality-of-life scores -, ROCKVILLE, M...Genome Sciences, Inc. today announced the top-line...uferon(R) (albinterferon alfa-2b),in combination w...otype 1 chronic hepatitis C. The Company expects t...
Other Medicine Technology:Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 2Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 3Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 4Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 6Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 7Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 8
(Date:11/20/2009)...nderstanding Brain Wiring and Diseases ,, WASHI...my Schmahmann, Professor of Neurology at Harvard M... General Hospital in Boston, on Thursday, November...w field of study called "Connectivity" at the laun...n is an award-winning leader in the field of the c...
(Date:11/20/2009).../ -- Following a recall by Unilever The Stop &...s Country Crock ® Side Dishes DELUXE Cheddar ...e Dishes DELUXE Four Cheese Pasta due to an undecl...ates and UPCs are affected: ,, Shedd,s Country...Rice 21 oz, UPC 027400218316, Best By NOV 29 09 th...
(Date:11/20/2009)...FirstCall/ -- Centene Corporation (NYSE: CNC )...of America Merrill Lynch 2009 Credit Conference, t...Hotel Times Square in New York City. ,, Centene... Eastern Time. Investors and other interested part...presentation at: http://www.veracast.com/webcasts...
(Date:11/20/2009)...-FirstCall/ -- SIRIUS XM Radio (Nasdaq: SIRI ) ...dio Reports: What Every Women Needs to Know About...n journalist Perri Peltz. ,, (Logo: http://ww...,, Doctor Radio Reports: What Every Woman Ne...21 live at 10:00 am ET on Doctor Radio , SIRIUS c...
(Date:11/20/2009)...gency medical service (EMS) providers in the Unite...ts each year. Only 5 to 10 percent of people who ...y cardiopulmonary resuscitation (CPR) provided by ...etter patient outcome. The Resuscitation Outcomes... network to study prehospital treatments for cardi...
Breaking Medicine News(10 mins):Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...sue swelling better than steroids, team says , ...-angiogenesis drugs reduce edema (swelling of brai...oblastomas, a new study suggests. , Anti-angiogene...ospital team found that the experimental anti-angi...
...ill be made available closer to the meeting date. ...ance of the meeting as well as during the meeting....esearch Council of the National Academy of Science...ip of more than 5,700 scientists is representative...
... April 2 /PRNewswire-Asia-FirstCall/ -- Genesis,Ph...d: GNPH) ("Genesis" or the,"Company"), a U.S. phar...n the,People,s Republic of China, today affirmed i...e guidance for its fiscal year ending June,30, 200...
...e Treatment by a Podiatrist May Lead to Long-Term ...oot problems such as bunions, corns and dry, crack...e particular ailment -- heel pain -- stands out am...20 Americans aged 18 and older, found that 39 perc...
... Corticon offers special pricing on patent-pe...nd managing engaging self-service web applications...EB) April 2, 2009 -- Corticon Technologies, Inc. (...nar about, its patent-pending Corticon DialogsTM ...
... Celebrity Stylist, Lauri Eisenberg, Offers H...n Doesn,t Control Your Wardrobe , ...you,d never consider wearing silk or even solid co... waterworks going on underneath, then perspiration...
Other Medicine News:Health News:Drug Improves Survival in Mice With Brain Tumors 2Health News:Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009 2Health News:Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009 3Health News:Survey Shows Nearly 40 Percent of Americans Reel From Heel Pain 2Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 2Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 3Health News:Don't Sacrifice Style Because of Sweat 2Health News:Don't Sacrifice Style Because of Sweat 3Health News:Don't Sacrifice Style Because of Sweat 4
Lumenis 950 Slit Lamp
Novus 3000 532 nm Laser System
Selecta Duo Photocoagulator Combination Laser
EnTrust Single Chamber ICD
Medicine Products: